| Symbol | ALMS |
|---|---|
| Name | ALUMIS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 280 EAST,GRAND AVENUE, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | 650-231-6625 |
| Fax | — |
| — | |
| Website | https://www.alumis.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001847367 |
| Description | Alumis mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis, and is currently being evaluated in additional Phase 2 clinical trials in patients with systemic lupus erythematosus (SLE) and non-infectious uveitis, for which we expect to report results in 2026 and by the end of 2024, respectively. Additional info from NASDAQ: |
Pangali Sanam 🟡 adjusted position in 5.0K shares (1 derivative) of ALUMIS INC. (ALMS) at $28.00 Transaction Date: Jul 06, 2026 | Filing ID: 000005
Read more📋 SANAMPREET PANGALI (Officer) plans to sell 5K shares of ALUMIS INC. (at $28.00 each, total $140K) Filed: Jul 06, 2026 | ID: 006850
Read moreTETRAULT LYNN A. 🟢 acquired 19.1K shares (1 derivative) of ALUMIS INC. (ALMS) at $28.14 Transaction Date: Jun 30, 2026 | Filing ID: 000003
Read moreYao Zhengbin 🟢 acquired 19.1K shares (1 derivative) of ALUMIS INC. (ALMS) at $28.14 Transaction Date: Jun 30, 2026 | Filing ID: 000004
Read moreSrivastava Sapna 🟢 acquired 19.1K shares (1 derivative) of ALUMIS INC. (ALMS) at $28.14 Transaction Date: Jun 30, 2026 | Filing ID: 000005
Read moreMachado Patrick 🟢 acquired 19.1K shares (1 derivative) of ALUMIS INC. (ALMS) at $28.14 Transaction Date: Jun 30, 2026 | Filing ID: 000006
Read moreAKKARAJU SRINIVAS 🟢 acquired 19.1K shares (1 derivative) of ALUMIS INC. (ALMS) at $28.14 Transaction Date: Jun 30, 2026 | Filing ID: 000011
Read more(10% Negative) ALUMIS INC. (ALMS) Announces Delay in used Development Timeline Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreDrappa Jorn 🟡 adjusted position in 0 shares (2 derivative) of ALUMIS INC. (ALMS) at $8.84 Transaction Date: May 22, 2026 | Filing ID: 000005
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06952634 | An Investigational Study of ESK-001 in Participants With Normal Liver Function … | Phase1 | Hepatic Impairment | Completed | 2025-04-29 | 2026-03-24 | ClinicalTrials.gov |
| NCT06962774 | An Investigational Study of ESK-001 in Participants With Normal Renal Function … | Phase1 | Renal Impairment | Completed | 2025-04-23 | 2025-08-01 | ClinicalTrials.gov |
| NCT06846541 | Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis | Phase3 | Plaque Psoriasis | Active_Not_Recruiting | 2025-01-08 | 2028-11-01 | ClinicalTrials.gov |
| NCT06588738 | A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Ef… | Phase3 | Plaque Psoriasis | Completed | 2024-08-20 | 2025-12-18 | ClinicalTrials.gov |
| NCT06586112 | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderat… | Phase3 | Plaque Psoriasis | Completed | 2024-07-25 | 2025-11-20 | ClinicalTrials.gov |
| NCT07442149 | An Investigational Study to Evaluate the Safety and Tolerability of Single and … | Phase1 | Healthy Volunteer | Completed | 2024-04-22 | 2024-12-18 | ClinicalTrials.gov |
| NCT05966480 | Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 i… | Phase2 | SLE | Active_Not_Recruiting | 2023-06-26 | 2027-09-01 | ClinicalTrials.gov |
| NCT05953688 | POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Activ… | Phase2 | Uveitis Posterior Non-Infectious | Terminated | 2023-06-14 | 2024-08-13 | ClinicalTrials.gov |
| NCT05739435 | Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK… | Phase2 | Plaque Psoriasis | Active_Not_Recruiting | 2023-01-17 | 2026-12-30 | ClinicalTrials.gov |
| NCT05431634 | Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy … | Phase1 | Safety and Tolerability | Completed | 2022-05-12 | 2022-12-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | SLE | ACTIVE_NOT_RECRUITING | NCT05966480 |
| Envudeucitinib | Other | Phase PHASE2 | SLE | ACTIVE_NOT_RECRUITING | NCT05966480 |
| envudeucitinib | Other | Phase PHASE2 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT05739435 |
| envudeucitinib | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT06952634 |
| envudeucitinib | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT06952634 |
| envudeucitinib | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT06952634 |
| envudeucitinib | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT06952634 |
| envudeucitinib | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT06952634 |
| envudeucitinib | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT06952634 |
| Placebo | Other | Phase PHASE1 | Safety and Tolerability | COMPLETED | NCT05431634 |
| Experimental drug: ESK-001 | Drug | Phase PHASE1 | Safety and Tolerability | COMPLETED | NCT05431634 |
| ESK-001 | Other | Phase PHASE2 | Uveitis Posterior Non-Infectious | TERMINATED | NCT05953688 |
| ESK-001 | Other | Phase PHASE1 | Hepatic Impairment | RECRUITING | NCT06952634 |
| ESK-001 | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT06962774 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07442149 |
| A-005 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07442149 |
| envudeucitinib | Other | Phase PHASE2 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT05739435 |
| Placebo | Other | Phase PHASE2 | SLE | ACTIVE_NOT_RECRUITING | NCT05966480 |
| Envudeucitinib | Other | Phase PHASE2 | SLE | ACTIVE_NOT_RECRUITING | NCT05966480 |
| Placebo | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06846541 |
| Blinded Envudeucitinib | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06846541 |
| Open-Label Envudeucitinib | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06846541 |
| Apremilast | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06588738 |
| Placebo | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06588738 |
| Envudeucitinib | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06588738 |
| Placebo | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06586112 |
| Apremilast | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06586112 |
| Envudeucitinib | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06586112 |
| Placebo | DRUG | Phase PHASE2 | SLE | ACTIVE_NOT_RECRUITING | NCT05966480 |
| Envudeucitinib | DRUG | Phase PHASE2 | SLE | ACTIVE_NOT_RECRUITING | NCT05966480 |
| envudeucitinib | DRUG | Phase PHASE2 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT05739435 |